246 related articles for article (PubMed ID: 22508833)
1. Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.
Loan Le TY; Mardini M; Howell VM; Funder JW; Ashton AW; Mihailidou AS
Hypertension; 2012 Jun; 59(6):1164-9. PubMed ID: 22508833
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction.
Mihailidou AS; Loan Le TY; Mardini M; Funder JW
Hypertension; 2009 Dec; 54(6):1306-12. PubMed ID: 19841288
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.
Michea L; Villagrán A; Urzúa A; Kuntsmann S; Venegas P; Carrasco L; Gonzalez M; Marusic ET
Hypertension; 2008 Aug; 52(2):295-300. PubMed ID: 18591458
[TBL] [Abstract][Full Text] [Related]
5. AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion.
Marques-Neto SR; Ferraz EB; Rodrigues DC; Njaine B; Rondinelli E; Campos de Carvalho AC; Nascimento JH
Cardiovasc Drugs Ther; 2014 Apr; 28(2):125-35. PubMed ID: 24258356
[TBL] [Abstract][Full Text] [Related]
6. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of spironolactone on endothelial cell apoptosis.
Williams TA; Verhovez A; Milan A; Veglio F; Mulatero P
Endocrinology; 2006 May; 147(5):2496-505. PubMed ID: 16497808
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?
Chai W; Garrelds IM; de Vries R; Danser AH
Hypertension; 2006 Apr; 47(4):665-70. PubMed ID: 16490840
[TBL] [Abstract][Full Text] [Related]
9. Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in vitro.
Sánchez-Más J; Turpín MC; Lax A; Ruipérez JA; Valdés Chávarri M; Pascual-Figal DA
Rev Esp Cardiol; 2010 Jul; 63(7):779-87. PubMed ID: 20609311
[TBL] [Abstract][Full Text] [Related]
10. Novel cardiac apoptotic pathway: the dephosphorylation of apoptosis repressor with caspase recruitment domain by calcineurin.
Tan WQ; Wang JX; Lin ZQ; Li YR; Lin Y; Li PF
Circulation; 2008 Nov; 118(22):2268-76. PubMed ID: 19001025
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
Yasuoka S; Kai H; Kajimoto H; Kudo H; Takayama N; Anegawa T; Koga M; Miyamoto T; Mifune H; Kage M; Hirooka Y; Imaizumi T
Circ J; 2013; 77(6):1474-81. PubMed ID: 23470864
[TBL] [Abstract][Full Text] [Related]
13. Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade.
Rafatian N; Westcott KV; White RA; Leenen FH
Am J Physiol Regul Integr Comp Physiol; 2014 Oct; 307(7):R879-87. PubMed ID: 25100076
[TBL] [Abstract][Full Text] [Related]
14. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
[TBL] [Abstract][Full Text] [Related]
15. [Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction].
Hayashi M
J Cardiol; 2004 Feb; 43(2):88-91. PubMed ID: 15046031
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions.
Wang H; Shimosawa T; Matsui H; Kaneko T; Ogura S; Uetake Y; Takenaka K; Yatomi Y; Fujita T
J Hypertens; 2008 Jul; 26(7):1453-62. PubMed ID: 18551023
[TBL] [Abstract][Full Text] [Related]
18. ARC is a critical cardiomyocyte survival switch in doxorubicin cardiotoxicity.
An J; Li P; Li J; Dietz R; Donath S
J Mol Med (Berl); 2009 Apr; 87(4):401-10. PubMed ID: 19139834
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation.
Veliotes DG; Woodiwiss AJ; Deftereos DA; Gray D; Osadchii O; Norton GR
Hypertension; 2005 May; 45(5):914-20. PubMed ID: 15837836
[TBL] [Abstract][Full Text] [Related]
20. Role of Nongenomic Signaling Pathways Activated by Aldosterone During Cardiac Reperfusion Injury.
Ashton AW; Le TY; Gomez-Sanchez CE; Morel-Kopp MC; McWhinney B; Hudson A; Mihailidou AS
Mol Endocrinol; 2015 Aug; 29(8):1144-55. PubMed ID: 26121234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
